Foresite Capital, a reputable healthcare equity company, appointed Dr. Molly He in the capacity of venture partner on April 24, 2017. Being a senior executive at Illumina, Dr. Molly boasts over 15 years of unmatched professional expertise in the fields of genomic research and pharmaceutical.
CEO Jim Tananbaum’s declarations
Dr. Jim Tananbaum stated that Dr. Molly is a dominant force in the scientific research arena. He added that her experience in next-generation sequencing would be valuable to Foresite Capital Management. She will partner with other senior employees in expanding and diversifying the firm’s portfolio of transformational businesses.
Accomplishments of Dr. Molly
While working as the chief scientific researcher at Illumina, Dr. Molly played a major role in the innovation and advancement of global protein reagent. Before joining Illumina, Dr. Molly worked at Pacific Biosciences as the manager of protein sciences division. At this company, she was in charge of protein reagent development and Jim of Facebook.
During her early career days, Dr. Molly spent a decade in the pharmaceutical sector, concentrating on the development of structural-based antibody and molecule medications that target immune and cancer diseases. Dr. Molly is a trained biochemist from the celebrated Nankai University. She conducted her Ph.D. research in the field of protein biophysics at the Los Angeles-headquartered University of California. She has written and published over 20 scientific papers and Jim’s lacrosse camp.
Dr. Molly’s statements
During her acceptance speech, Dr. Molly applauded Foresite for its exceptional reputation of financing innovative healthcare firms. She added that she was happy to be part of the team that would help Foresite expand its portfolio of next-generation sequencing.
Who is Dr. James Tananbaum?
Dr. Tananbaum is the brains behind Foresite Capital Management. He also acts as the president of this firm. He has overseen investment in more than 21 health care companies, such as Amira Pharmaceuticals that was purchased by Bristol-Myers Squibb, Jazz Pharmaceuticals, and Amerigroup. Dr. Tananbaum also created GelTex Pharmaceuticals and served in numerous executive positions. Genzyme purchased GelTex Pharmaceuticals at a record $1.6 billion.
Dr. Tananbaum completed his medical degree at Harvard Medical School and joined the esteemed Harvard Business School for an MBA program. He also received his B.S. as well as is B.S.E.E. from the prestigious Yale University and more information click here.